Grant ID RP240293
Awarded On February 21, 2024
Title Therapeutic vulnerabilities and predictors of response to chemo(immuno)therapy in patients with high-risk, early stage triple-negative breast cancer (TNBC)
Program Academic Research
Award Mechanism Individual Investigator Research Awards for Computational Biology
Institution/Organization The University of Texas M.D. Anderson Cancer Center
Principal Investigator/Program Director Anil Korkut
Cancer Sites Breast
Contracted Amount $1,199,999*

*Pending contract negotiation

Lay Summary

In the United States, breast cancer is the most common cancer among women. Characterized by a lack of clinically useful markers associated with other breast cancer subtypes that can direct effective therapeutic interventions, triple-negative breast cancer (TNBC) is an aggressive subtype with an urgent need for novel and effective therapy strategies. TNBC is also more common in younger, African American, and Hispanic women, posing major challenges as a cancer-related disparity. In patients with localized TNBC, response to chemo and immunotherapy preoperatively is associated with excellent long-term survival while lack of response is linked to a significantly higher risk of metastatic disease...

Read More